Glasgow, UK: REPROCELL employees, Zara Puckrin and Graeme Macluskie, have published a headline article in the latest issue of European Biopharmaceutical Review (EBR).
The piece, titled "Human Fresh Tissue VS Clinical Attrition", explains the benefits of human fresh tissue testing in drug discovery, describing studies where these assays have helped compounds pass clinical trial. Examples provided include studies by Roche, Amgen, and the International Partnership for Microbicides.
"At REPROCELL, have understood the power of human fresh tissue testing for decades", explained Dr David Bunton, CEO of REPROCELL Europe and Founder of Biopta. "We believe that, as the world moves towards more stratified approaches to drug prescribing, these assays will become even more valuable", he continued.
EBR is a quarterly publication that provides information on the European biopharmaceutical market. Its readership includes scientists across Europe, North America, and beyond. You can read the full article on the EBR website here.
Sign up to receive information from REPROCELL about our products, services, applications, promotions, and news (includes a weekly blog update email).
Zara Puckrin, BSc / 5 July 2021
Zara Puckrin, BSc / 29 June 2021
Yu Takeo / 21 June 2021
© 2021 REPROCELL Inc. All rights reserved.